



Viapath Customer and Corporate Services
Francis House
9 King's Head Yard
London, SE1 1NA
020 4513 7300
customerservices@viapath.org

2nd February 2021

To whom it may concern,

We are writing to inform you of some changes to the reporting of creatinine as part of the urine drug screen assay that is conducted within the Integrated Toxicology Unit (Viapath), based at King's College Hospital NHS Foundation Trust. These changes will take effect from Monday 15th February 2021.

As part of the urine drug screen assay, creatinine is used as a sample integrity check and should not be interpreted as a measure of renal function. Consequently, creatinine will now be reported qualitatively under the test name 'Specimen Validity' with one of the following comments:

- Sample valid (creatinine within expected range)
- Dilute sample (creatinine <2 mmol/L)
- Extremely dilute sample (creatinine <0.5 mmol/L)

Please note that urine samples from babies are often dilute and this does not invalidate results.

Please do not hesitate to contact us if you have any questions.

Yours faithfully,

Royce Vincent
Clinical Director of Pathology
Department of Clinical Biochemistry
King's College Hospital

Colin Stone
Service Delivery Manager
Reference Chemistry laboratories
King's College Hospital